<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03849820</url>
  </required_header>
  <id_info>
    <org_study_id>OpeRa-2018</org_study_id>
    <nct_id>NCT03849820</nct_id>
  </id_info>
  <brief_title>Open vs Robotic Assisted Partial Nephrectomy</brief_title>
  <acronym>OpeRa</acronym>
  <official_title>Open vs Robotic Assisted Partial Nephrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intuitive Surgical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intuitive Surgical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate that Robotic-Assisted partial nephrectomy is superior to Open partial
      nephrectomy in reducing the number of 30 day post-operative complications (Clavien-Dindo Type
      I-V) for patients with intermediate to high complexity kidney tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Partial nephrectomy is the surgical removal of a kidney tumor while unaffected tissue remains
      intact so that the kidney function is maintained as far as possible. The more radical
      procedure would be the complete removal of the kidney, which is not examined in this trial.

      Surgery will be randomized either to an open technique involving a large incision or the
      robotic assisted technique with a few small incisions (keyhole surgery). With robotic
      assisted surgery the movements of the surgeon are translated into the movement of the
      instruments.

      It is not clear which of the two procedures, open or robotic assisted, has less
      complications. It is expected that these are different due to the different level of
      invasiveness and the level of direct access to the organ. This study aims to show that
      robotic assisted surgery results in less complications than open surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2019</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30 day complications</measure>
    <time_frame>Day of surgery to 30th post operative day</time_frame>
    <description>Any complication that occurred within 30 days post surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Operative time</measure>
    <time_frame>Day of surgery</time_frame>
    <description>Timing of surgical steps in the OR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia time</measure>
    <time_frame>Day of surgery</time_frame>
    <description>Period in which the kidney has no blood supply</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical radicality conversions</measure>
    <time_frame>Day of surgery</time_frame>
    <description>Conversion from robotic to open, partial to radical</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative blood loss</measure>
    <time_frame>Day of surgery</time_frame>
    <description>Volume of blood loss during the surgical procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment</measure>
    <time_frame>Baseline until Day 90</time_frame>
    <description>Assessment of pain level via the Brief Pain Inventory (BPI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Medication</measure>
    <time_frame>Baseline until Day 90</time_frame>
    <description>Recording pain medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathic pain</measure>
    <time_frame>Baseline and Day 30 and Day 90</time_frame>
    <description>Development of neuropathic pain via the DN-4 Patient interview questions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney function via the estimated glomerular filtration rate (eGRF)</measure>
    <time_frame>Baseline until Day 5 / discharge (whatever is earlier)</time_frame>
    <description>Data will be gathered from routine examination, not a mandatory assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post operative complications</measure>
    <time_frame>Day 90</time_frame>
    <description>Any Clavien-Dindo I-V post-operative complication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>Discharge</time_frame>
    <description>Time from surgery to discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure related readmissions</measure>
    <time_frame>Day 90</time_frame>
    <description>Readmission that can be linked to the partial nephrectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure related reoperations</measure>
    <time_frame>Day 90</time_frame>
    <description>Re-operation that can be linked to the partial nephrectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of recovery from the intervention</measure>
    <time_frame>Baseline until Day 5 / discharge (whatever is earlier)</time_frame>
    <description>Quality of recovery questionnaire QoR-9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire, generic measure</measure>
    <time_frame>Baseline until Day 90</time_frame>
    <description>EQ-5D 5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire, cancer patient specific</measure>
    <time_frame>Baseline until Day 90</time_frame>
    <description>EORTC QLQ-C30</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">606</enrollment>
  <condition>Renal Cancer</condition>
  <arm_group>
    <arm_group_label>Robotic-assisted partial nephrectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>da Vinci surgical robotic assisted partial nephrectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open partial nephrectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Open partial nephrectomy surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Robotic-assisted partial nephrectomy</intervention_name>
    <description>Application of the da Vinci surgical robot to assist the partial nephrectomy</description>
    <arm_group_label>Robotic-assisted partial nephrectomy</arm_group_label>
    <other_name>da Vinci, RAS, dVPN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Open partial nephrectomy</intervention_name>
    <description>Open surgery to conduct the partial nephrectomy</description>
    <arm_group_label>Open partial nephrectomy</arm_group_label>
    <other_name>Open surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Patient with a renal tumor that is a candidate for OPEN surgery and robotic assisted
             surgery (RAS) partial nephrectomy (PN)

          -  R.E.N.A.L. score ≥ 7

          -  eGFR ≥ 50 ml/min/1.73 m²

          -  Anticoagulation is accepted according to the surgeon's practice

        Exclusion Criteria:

          -  Solitary kidney or functionally solitary kidney

          -  Prior surgery at the affected kidney excluding endoscopic kidney stone surgery

          -  Bilateral tumors

          -  Multiple renal tumors requiring excision

          -  Renal vein tumor thrombus

          -  Likely insufficient volume of remaining parenchyma after partial nephrectomy to
             maintain viable kidney remnant

          -  Metastatic disease with life expectancy of less than 1 year

          -  Pregnancy or suspected pregnancy

          -  Planned concomitant procedure

          -  Subject who is unable or unwilling to comply with the protocol requirements

          -  Subject considered to be from a vulnerable population according to IS0 14155:2011
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc O Grimm, MD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology, University Hospital Jena</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arnulf Stenzl, MD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Urology, University Hospital Tübingen, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Appenrodt, PhD</last_name>
    <phone>+49 173 2043740</phone>
    <email>peter.appenrodt@intusurg.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole Lundberg</last_name>
    <phone>+41 21 8215614</phone>
    <email>nicole.lundberg@intusurg.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Urology, Alfried Krupp Krankenhaus Rüttenscheid</name>
      <address>
        <city>Essen</city>
        <zip>45131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Buse, MD</last_name>
      <phone>+49 201 8051132</phone>
      <email>urologie@krupp-krankenhaus.de</email>
    </contact>
    <contact_backup>
      <last_name>Nicole Müller</last_name>
      <phone>+49 201 43441629</phone>
      <email>urologie@krupp-krankenhaus.de</email>
    </contact_backup>
    <investigator>
      <last_name>Stephan Buse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carolin Hach, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Urology, University Hospital Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Gratzke, Prof, MD</last_name>
      <phone>+49 761 27028910</phone>
      <email>christian.gratzke@uniklinik-freiburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Wael Khoder, Prof, MD</last_name>
      <phone>+49 761 27028910</phone>
      <email>wael.khoder@uniklinik-freiburg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Christian Gratzke, Prof, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wael Khoder, Prof, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik und Poliklinik für Urologie</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Fornara, MD, Prof</last_name>
      <phone>+49 3455 571446</phone>
      <email>direktor.urologie@uk-halle.de</email>
    </contact>
    <contact_backup>
      <last_name>Nasreldin Mohammed, MD</last_name>
      <phone>+49 3455 571446</phone>
      <email>nasreldin.mohammed@uk-halle.de</email>
    </contact_backup>
    <investigator>
      <last_name>Paolo Fornara, MD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nasreldin Mohammed, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg, Urologische Klinik</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne N Nyarangi-Dix, MD</last_name>
      <phone>+49 6221 56-8820</phone>
      <email>Joan.Nyarangi-Dix@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Gencay Hatiboglu, MD</last_name>
      <phone>+49 6221 56-8820</phone>
      <email>Gencay.Hatiboglu@med.uni-heidelberg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Joanne Nyarangi-Dix, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Markus Hohenfellner, MD, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gencay Hatiboglu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georgi Tosev, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Urologie, Marien Hospital Herne</name>
      <address>
        <city>Herne</city>
        <zip>44625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Department of Urology - Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanja Lauer</last_name>
      <phone>+49 (0) 68 41 1624787</phone>
      <email>studienzentrale@uks.eu</email>
    </contact>
    <contact_backup>
      <last_name>Vera Mathei-Mayer</last_name>
      <phone>+49 (0) 68 41 1624787</phone>
      <email>studienzentrale@uks.eu</email>
    </contact_backup>
    <investigator>
      <last_name>Stefan Siemer, MD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Stöckle, MD, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Urology, University Hospital Jena</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc-Oliver Grimm, MD, Prof</last_name>
      <phone>+49 3641 9329901</phone>
      <email>nora.hesse@med.uni-jena.de</email>
    </contact>
    <contact_backup>
      <last_name>Nora Hesse</last_name>
      <phone>+49 3641 9329901</phone>
      <email>nora.hesse@med.uni-jena.de</email>
    </contact_backup>
    <investigator>
      <last_name>Marc-Oliver Grimm, MD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susan Foller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Urologie, Marien-Hospital Marl</name>
      <address>
        <city>Marl</city>
        <zip>45768</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans-Jörg Sommerfeld, MD</last_name>
      <phone>+49 2365 911261</phone>
      <email>dr.h.sommerfeld@kkrn.de</email>
    </contact>
    <contact_backup>
      <last_name>Frank Rehkugler, MD</last_name>
      <phone>+49 2365 911261</phone>
      <email>dr.f.rehkugler@kkrn.de</email>
    </contact_backup>
    <investigator>
      <last_name>Hans-Jörg Sommerfeld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frank Rehkugler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sebastian Gabler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Klinikum rechts der Isar der Technischen Universität</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Heck, MD</last_name>
      <phone>+49 89 41402508</phone>
      <email>Matthias.Heck@tum.de</email>
    </contact>
    <contact_backup>
      <last_name>Michael Autenrieth, MD</last_name>
      <phone>+49 89 41402508</phone>
      <email>Michael.Autenrieth@tum.de</email>
    </contact_backup>
    <investigator>
      <last_name>Matthias Heck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Autenrieth, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Veronika Goethe</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marion Jäger</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Diakonie Klinikum</name>
      <address>
        <city>Stuttgart</city>
        <zip>70176</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Schwentner, Prof, MD</last_name>
      <phone>+49 711 9912301</phone>
      <email>sekretariat-urologie@diak-stuttgart.de</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Seidl</last_name>
      <phone>+49 711 9912301</phone>
      <email>sekretariat-urologie@diak-stuttgart.de</email>
    </contact_backup>
    <investigator>
      <last_name>Christian Schwentner, Prof, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Urology, University Hospital Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnulf Stenzl, MD, Prof</last_name>
      <phone>+49 7071 2986000</phone>
      <email>uro-studien@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Jens Bedke, MD, Prof</last_name>
      <phone>+49 7071 2986000</phone>
      <email>uro-studien@med.uni-tuebingen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Arnulf Stenzl, MD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jens Bedke, MD, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 15, 2019</study_first_submitted>
  <study_first_submitted_qc>February 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2019</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Robotic-assisted Surgery</keyword>
  <keyword>Open Surgery</keyword>
  <keyword>Partial Nephrectomy</keyword>
  <keyword>minimal invasive surgery</keyword>
  <keyword>RAS</keyword>
  <keyword>MIS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

